NASDAQ:ERNA Ernexa Therapeutics Q3 2025 Earnings Report $3.97 -0.11 (-2.62%) As of 12:15 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Ernexa Therapeutics EPS ResultsActual EPS-$3.75Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AErnexa Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AErnexa Therapeutics Announcement DetailsQuarterQ3 2025Date11/7/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsErnexa Therapeutics' next earnings date is estimated for Friday, November 6, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Ernexa Therapeutics Earnings HeadlinesErnexa Therapeutics Inc.: Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy ...September 15 at 3:42 PM | finanznachrichten.deErnexa Reports Positive ERNA-201 Preclinical Data; Advances ERNA-101 Toward Q4 2026 INDSeptember 15 at 3:42 PM | rttnews.com“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI company holding 150 patents for technology that processes information up to 1,000 times faster than standard AI. Wall Street projects the company's sales to more than triple in the coming year, and Brown notes it's roughly the same size Nvidia was a decade ago, with a key catalyst set for November 11.September 16 at 1:00 AM | Brownstone Research (Ad)Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First ...September 15 at 9:14 AM | markets.businessinsider.comErnexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human DosingSeptember 15 at 8:42 AM | globenewswire.comErnexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 14 at 9:05 AM | globenewswire.comSee More Ernexa Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ernexa Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ernexa Therapeutics and other key companies, straight to your email. Email Address About Ernexa TherapeuticsEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.View Ernexa Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Marex Stock Doubles on Record Profits, But Can the Rally Continue?The Ultimate Cyber Shield: CrowdStrike Rises Past $2352 "Cheap for a Reason" Airline Stocks That May Be Worth the RiskMarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks RiskyCould Dave & Buster’s Capitulation Signal the Bottom Is Finally In?Navan's Strong Quarter Meets an AI Spending Reality Check3 Defense Stocks Riding the High-Energy Laser Boom Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
